SpliceBio appoints David Favre as chief development officer

Spanish genetic medicines company SpliceBio today announced the appointment of David Favre as its chief development officer (CDO).

Dr Favre brings more than 25 years of experience in gene therapy, immunology and drug development throughout academia and the biopharma industry. He joins SpliceBio from Innoskel, where he served as chief scientific officer.

Prior to that, Dr Favre was vice president of translational medicine at Asklepios Biopharmaceutical (AskBio), where he led the platforms and program resources to marshal preclinical, investigational new drug (INDs) and early clinical programs, particularly focusing on the immunogenicity and adjunctive immunotherapy of AAV gene therapy and metabolic diseases. Previously Dr Favre was the Director of HIV Biology at GSK (LSE: GSK), where he spearheaded their portfolio of immunotherapy drugs.